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Abstract
 
Gene targeting of the adaptor molecule DAP12 in mice caused abnormal distribution and im-
paired antigen presentation capacity of dendritic cells (DCs). However, the DAP12-associated
receptors expressed on DCs and their functions have not been identified yet. Here we show
that the triggering receptor expressed on myeloid cells-2 (TREM-2) is a cell surface receptor
on human monocyte-derived DCs, which is associated with DAP12. TREM-2/DAP12 pro-
motes upregulation of CC chemokine receptor 7, partial DC maturation, and DC survival
through activation of protein tyrosine kinases and extracellular signal–regulated kinase. In con-
trast to Toll-like receptor-mediated signaling, TREM2/DAP12 stimulation is independent of
nuclear factor-
 
 
 
B and p38 stress-activated protein kinase. This novel DC activation pathway
may regulate DC homeostasis and amplify DC responses to pathogens, explaining the pheno-
type observed in DAP12-deficient mice.
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Introduction
 
Dendritic cells (DCs)
 
*
 
 are a distinct population of bone
marrow–derived leukocytes that initiate primary and sec-
ondary immune responses (1). DCs migrate from the blood
to peripheral tissues, where they reside in an immature state,
awaiting antigen encounter. Upon antigen capture, DCs
process them into peptides, which are loaded onto MHC
molecules for presentation to T cells. As a result of patho-
gen invasion, inflammation, and tissue damage, DCs receive
additional activating signals, which induce a profound
change in DC phenotype and functions, known as matura-
tion (1–3). Mature DCs express the chemokine receptor
CCR7, which interacts with the chemokines CCL19 (also
known as EBI-1 ligand chemokine [ELC], or macrophage
inflammatory protein 3 
 
 
 
 [MIP-3
 
 
 
]) and CCL21 (also
known as secondary lymphoid tissue chemokine [SLC], or
6-C-Kine) (4–9). These chemokines are crucial for guiding
DCs from peripheral tissues to draining lymph nodes, as
demonstrated in mice with natural or targeted genetic dele-
tions of CCL19, CCL21, or CCR7 (10–14). In addition,
mature DCs express high levels of stable MHC-peptide
complexes on the cell surface, upregulate costimulatory and
adhesion molecules, and downregulate antigen-capturing
molecules. Thus, mature DCs can efficiently present anti-
gens and stimulate virgin-T cells located in the T cell–rich
areas of lymph nodes (1, 15). Here, DCs receive further ac-
tivating signals from cognate Th cells, which express CD40
ligand (CD40L) (16), OX40 (17, 18), and TNF-related
activation-induced cytokine (TRANCE) (19–22). These
stimuli trigger IL-12 secretion by antigen presenting DCs
thus promoting Th1 type T cell responses (20, 23–27).
Activating signals induce DC maturation through several
distinct signaling pathways. LPS, other bacterial and viral
components, as well as products released by damaged tis-
sues, activate DCs through Toll-like receptors (TLRs) (28,
29). TLRs trigger downstream signaling pathways, which
activate the nuclear factor (NF)-
 
 
 
B. NF-
 
 
 
B promotes the
transcription of a variety of genes mediating maturation
(30–33). In addition, TLRs activate mitogen-activated pro-
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tein kinases (MAPKs), such as the stress-activated protein
kinase p38 (P38/SAPK) and the extracellular signal–regu-
lated kinase (ERK), which concur to DC activation (28,
29). Inflammatory cytokines, such as IL-1, IL-18, and
TNF-
 
 
 
, and T cell surface molecules, such as CD40L,
OX40, and TRANCE, bind specific receptors that activate
NF-
 
 
 
B as well (1, 20, 34–37). A second pathway of DC
maturation is initiated by the receptors for the Fc portion
of IgG (FcRs), which bind antibody-opsonized pathogens
(38). FcRs lack intracellular signaling motifs, but display a
charged residue in the transmembrane domain, which me-
diates association with the 
 
 
 
 chain of FcR (FcR
 
 
 
) (39).
FcR
 
 
 
 contains a cytoplasmic immunoreceptor tyrosine-
based activation motif (ITAM), which recruits protein ty-
rosine kinases (PTKs) of the 
 
src
 
 and 
 
syk
 
 families. PTKs trig-
ger protein tyrosine phosphorylation, Ca
 
2
 
 
 
 mobilization,
and phosphorylation of several MAPKs (40, 41). While
FcR
 
 
 
 is essential for FcR-mediated DC maturation (42),
the role of downstream PTKs and MAPKs is yet unknown.
Recent observations suggest that DC activation is con-
trolled by yet another signaling pathway, which involves
the adaptor molecule DAP12 (also called KARAP).
DAP12 is associated with several NK and myeloid cells ac-
tivating receptors (43–54). Like FcR
 
 
 
, DAP12 contains a
cytoplasmic ITAM, recruits the PTKs ZAP70 and p72/syk,
and promotes activation of ERK (44, 45, 55, 56). Knock-
in mice bearing a nonfunctional mutation within the
ITAM of DAP12 showed a dramatic accumulation of DCs
in mucocutaneous epithelia and were resistant to hapten-
specific contact sensitivity (57). In addition, DAP12-defi-
cient mice were resistant to experimental autoimmune en-
cephalomyelitis (EAE) induced by immunization with my-
elin oligodendrocyte glycoprotein peptide (58). These
phenotypes suggested a role of DAP12 in regulating migra-
tion and antigen presentation capacity of DCs. Three
DAP12-associated receptors have been identified in my-
eloid cells. One of these, myeloid DAP12-associating lec-
tin-1 (MDL-1), is a member of the C-type lectin superfam-
ily (50). The others, signal-regulatory protein 
 
 
 
 (SIRP-
 
 
 
) and
triggering receptor expressed on myeloid cells-1 (TREM-
1), belong to the Ig superfamily (53, 59). TREM-1 is pref-
erentially expressed on neutrophils and a subset of blood
monocytes (53). SIRP-
 
 
 
 and MDL-1 are mainly expressed
on blood monocytes and macrophages (50, 60). When
monocytes are differentiated toward DCs by culturing
them in vitro in the presence of GM-CSF and IL-4, ex-
pression of MDL-1, SIRP-
 
 
 
, and TREM-1 is completely
downregulated (50, 53, 60).
Recently, we have cloned a cell surface receptor dis-
tantly related to TREM-1 called TREM-2. TREM-2 is a
member of the Ig-superfamily characterized by a single
V-type extracellular domain, a transmembrane region with
a charged residue of lysine and a short cytoplasmic tail with
no signaling motifs (53). Here we found that TREM-2 is
associated with DAP12 and, in contrast to TREM-1,
SIRP-
 
 
 
, and MDL-1, is not expressed on monocytes, but
it is strongly upregulated on human DCs derived in vitro
from monocytes. This observation provided the opportu-
nity to investigate the role of TREM2/DAP12-mediated
signaling pathways in DC migration and maturation.
 
Materials and Methods
 
Production of TREM-2 Human IgM Fusion Protein.
 
Soluble
TREM-2 was produced as a chimeric protein consisting of
TREM-2 extracellular domain and human IgM constant regions
(TREM-2 human IgM [TREM-2-HuIgM]), as previously de-
scribed (61). TREM-2 extracellular domain was amplified from
the cloned full length cDNA by polymerase chain reaction using
the following oligonucleotides: 5
 
 
 
-ACTCTGCTTCTGCCCT-
TGGCTGGGG, 3
 
 
 
-tagtagGTCGACATACTTACCGGGTGG-
GAAAGGGATTTCTCCTTCCAA. Purification of TREM-2-
HuIgM from culture supernatants was performed by affinity chro-
matography on Sepharose-coupled mouse anti–human IgM mAb
(Sigma-Aldrich) according to manufacturer’s protocols.
 
Transfections.
 
293 cells were transiently transfected with a
cDNA encoding human TREM-2 as a FLAG peptide NH
 
2
 
-ter-
minal fusion protein (Eastman Kodak Co.) using cytofectene
(Bio-Rad Laboratories).
 
Production and Modifications of Anti–TREM-2 and Control
mAbs.
 
6-wk-old BALB/c mice (Iffa-Credo) were immunized
with purified TREM-2-HuIgM. Spleen cells were fused with the
SP2/0 myeloma cells and hybridoma supernatants were screened
by ELISA using TREM-2-HuIgM as capturing protein and hu-
man-adsorbed horseradish peroxidase (HRP)-labeled goat anti–
mouse IgG (BD PharMingen) as detecting Ab. ELISA-positive
hybridoma supernatants were then tested by flow cytometry for
staining 293 cells expressing FLAG-tagged TREM-2. mAb 29E3
(anti–TREM-2, IgG1,
 
 
 
), mAb 21C7 (control IgG1, 
 
 
 
, anti–
TREM-1) (53), and mAb 1B7.11 (control IgG1, 
 
 
 
, anti-2,4,6
TNP; American Type Culture Collection) were purified using
GammaBind-Sepharose (Amersham Pharmacia Biotech). Purified
mAbs were either biotinylated (Roche) or labeled with Cy5
(Amersham Pharmacia Biotech) according to manufacturer’s pro-
tocols. F(ab
 
 
 
) or F(ab
 
 
 
)
 
2
 
 fragments of mAb 29E3 and mAb 21C7
were prepared using the F(ab
 
 
 
)/F(ab
 
 
 
)
 
2
 
 Kit (Pierce Chemical
Co.). F(ab
 
 
 
) and F(ab
 
 
 
)
 
2
 
 were separated from the Fc portion by
affinity chromatography on protein G-sepharose, followed by gel
filtration on a Superdex 75 HR10/30 (Amersham Pharmacia
Biotech). F(ab
 
 
 
) and F(ab
 
 
 
)
 
2
 
 preparations were tested for the ab-
sence of Fc fragments by immunoassay. F(ab
 
 
 
) and F(ab
 
 
 
)
 
2
 
 frag-
ments were biotinylated allowing for crosslinking by ExtrAvidine
(Sigma-Aldrich) or flow cytometry by Streptavidin-allophycocya-
nin (APC) or -PE (BD PharMingen). Alternatively, F(ab
 
 
 
)
 
2
 
 frag-
ments were crosslinked using a goat anti–mouse IgG F(ab
 
 
 
)
 
2
 
 spe-
cific antibody (The Jackson Laboratory).
 
Cells.
 
PBMCs were purified from human blood by gradient
density centrifugation on lymphocyte separation medium (LSM;
ICN Biomedicals/Cappel). CD14
 
 
 
 monocytes were purified
from PBMCs by magnetic cell sorting (MACS) using CD14 Mi-
croBeads (Miltenyi Biotec). Monocyte-derived DCs were pre-
pared from purified monocytes as described previously (62, 63).
 
Antibodies and Flow Cytometry.
 
Before staining, all cells were
preincubated with PBS-20% human serum for 1 h on ice to block
Fc receptors (FcR). Monocytes cultured in M-CSF or GM-CSF
and IL-4 were stained with either mAb 29E3, mAb 21C7, or
mAb 1B7.11, followed by human-adsorbed PE-conjugated goat
anti–mouse IgG (Southern Biotechnology Associates, Inc.). In
three-color stainings, immature DCs cultured with LPS (100 ng/
ml), TNF-
 
 
 
 (10 ng/ml), or CD40L-transfected J558L cells (64)
were incubated with Cy5-labeled mAbs 29E3 and FITC-conju- 
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gated anti-CD83 mAb (Immunotech). Cells were analyzed on a
FACSCalibur™ cytometer using CELLQuest™ software (Becton
Dickinson). Dead cells were excluded by gating on PI-negative
cells.
 
Stimulation of DCs by LPS, F(ab
 
 
 
)
 
2
 
 Anti–TREM-2 mAb, or
Human IgG in the Presence or Absence of Inhibitors.
 
Human IgG,
F(ab
 
 
 
)
 
2
 
 29E3 (anti–TREM-2 mAb), or control F(ab
 
 
 
)
 
2
 
 (21C7
anti–TREM-1 mAb) were coated for 6 h at 37
 
 
 
C on 96-well
flat-bottom plates with a final concentration of 20 
 
 
 
g/ml in PBS.
LPS was used at a final concentration of 1 
 
 
 
g/ml. Immature DCs
were plated at a concentration of 5 
 
 
 
 10
 
5
 
 cells/well and simulta-
neous contact to the plate was induced by short centrifugation
(400 
 
g
 
, 1 min, 25
 
 
 
C). Supernatants and cells were collected after
6, 12, 24, 36, 48, or 72 h and tested by ELISA or flow cytome-
try. In blocking experiments, inhibitors (PD98059 [20 
 
 
 
M],
LY294002 [10 
 
 
 
M], SB203580 [2 
 
 
 
M], PP2 [1 
 
 
 
M]; all from
Calbiochem), and TPCK (20 
 
 
 
M; Sigma-Aldrich) were added 60
min before stimulation.
 
Measurement of Cytokines, Chemokines, and Cell Surface Activation
Markers.
 
To measure stimulation-dependent changes in the ex-
pression of cell surface markers and cytokine secretion, mono-
cyte-derived DCs were stimulated as described above for 6, 12,
24, 48, and 72 h. Supernatants were collected and tested for pro-
duction of IL-6, IL-8, IL-10, TGF-
 
 
 
, IL-12p40, IL-12p75, IL-
13, IL-15, IL-18, IL-1
 
 
 
, IL-1
 
 
 
, TNF-
 
 
 
, and MCP-1 by ELISA
(BD PharMingen). Cells were harvested and stained with anti–
TREM-2, -MHC class I, -MHC class II, -CD1a, -CD11a,
-CD11b, -CD11c, -CD29, -CD32, -CD35, CD38-,
CD40-, -CD41, -CD54, -CD61, -CD64, -CD80, -CD83,
-CD86, -CD89, -CD103, -CD115, -CD116, -CCR5, -CCR6,
-CXCR4, or -Mannose receptor conjugated with Cy5-, PE-, or
FITC (all from Immunotech and BD PharMingen). Anti-CCR7
mAb (BD PharMingen) was followed by F(ab
 
 
 
)
 
2
 
 PE-labeled goat
anti–mouse IgM Ab (Southern Biotechnology Associates, Inc.).
Stained cells were analyzed by flow cytometry.
 
Measurement of Cytosolic Ca
 
2
 
 
 
.
 
Monocyte-derived DCs were
loaded with Indo-1 AM (Sigma-Aldrich) for 30 min at 37
 
 
 
C,
washed three times, and resuspended in RPMI/10 mM HEPES/
5% FCS. Cytoplasmic Ca
 
2
 
 
 
 levels were monitored in individual
cells by measuring 405/525 spectral emission ratio of loaded
Indo-1 dye by flow cytometry. After a baseline was acquired for
at least 30 s, 29E3, 21C7, F(ab
 
 
 
) 29E3, F(ab
 
 
 
) 21C7, F(ab
 
 
 
)
 
2
 
29E3, or F(ab
 
 
 
)
 
2
 
 21C7 were added to a final concentration of 1
 
 
 
g/ml and analysis was continued up to 512 s. All antibodies and
antibody fragments were biotinylated. In some experiments, Ex-
traAvidine (Sigma-Aldrich) was added as crosslinker together
with the biotinylated primary antibodies or Ab fragments.
 
Determination of ERK, JNK, and p38/SAPK Activation.
 
Monocyte-derived DCs (10
 
6
 
 cells per time point) were stimulated
as described above. After 0 (unstimulated control), 1, 2, 5, 10,
and 20 min cells were harvested and chilled on ice. Cells were
spun down and lysed in reducing sample buffer. Specific induc-
tion of tyrosine phosphorylation and phosphorylation of ERK,
p38/SAPK, and JNK was determined by reducing Western blot
analysis using anti–phospho-ERK, anti-ERK, anti–phospho-
p38/SAPK, anti-p38/SAPK, anti-phospho-JNK, and anti-JNK
antibodies (all from New England Biolabs, Inc.).
 
Surface Biotinylation and Pervanadate Treatment.
 
Monocyte-
derived DCs were washed three times in PBS followed by incuba-
tion with sulfo-NHS-biotin according to the manufacturer’s proto-
col (Pierce Chemical Co.). For pervanadate treatment, cells were
incubated with 200 
 
 
 
M pervanadate and 200 
 
 
 
M H
 
2
 
O
 
2
 
 at 37
 
 
 
C for
5 min. Biotinylation or pervanadate stimulation was stopped by wash-
ing the cells three times in PBS/10% FCS/200 
 
 
 
M pervanadate and
one time with ice cold PBS/200 
 
 
 
M pervanadate, respectively.
 
Immunoprecipitations.
 
Surface-biotinylated cells were lysed in
1% digitonin, 100 mM Tris-HCl, pH 7.4, 150 mM NaCl, pro-
tease inhibitors (Complete; Roche Molecular Biochemicals). Af-
ter overnight preclearing with normal mouse serum coupled to
protein G Sepharose 4B (Amersham Pharmacia Biotech), lysates
were subjected to immunoprecipitation with 5 
 
 
 
g/ml of 29E3,
21C7, or 1B7.11 at 4
 
 
 
C for 3 h. Immunocomplexes were precip-
itated by addition of protein-G-Sepharose 4B for 3 h at 4
 
 
 
C. Pre-
cipitates were washed four times with lysis buffer, followed by a
final wash with 0.5% digitonin, 100 mM Tris-HCl, pH7.4, 150
mM NaCl. After separation by SDS-PAGE, precipitates were an-
alyzed by Western blot with HRP-conjugated streptavidin. In
deglycosylation experiments the precipitates were incubated for
18 h with or without N-Glycanase F (Roche) according to the
manufacturer’s protocol. Pervanadate-treated cells were subjected
to immunoprecipitation as described above. Immunoprecipitates
were analyzed by Western blot with antiphosphotyrosine PY20-
HRP (Transduction Laboratories) or anti-DAP12 rabbit antise-
rum followed by human/mouse-adsorbed anti–rabbit IgG-HRP
(Southern Biotechnology Associates, Inc.).
 
Chemotaxis Assay.
 
Monocyte-derived human DCs (10
 
7
 
)
were treated for 24 h with F(ab
 
 
 
)
 
2
 
 21C7, F(ab
 
 
 
)
 
2
 
 29E3 coated on
plastic (20 
 
 
 
g/ml), or LPS (1 
 
 
 
g/ml). Cells (5 
 
 
 
 10
 
5 in 100  l
IMDM/0.5% BSA) were incubated for 1 h at 37 C. Cells were
subsequently loaded into collagen-coated Transwells (Costar;
3- m pore filter), which were placed onto 24-well plates con-
taining 450  l medium supplement with 100 ng/ml CCL19
(ELC/MIP-3 ) or CCL20 (6-C-Kine/SLC) (both from Pepro-
Tech). After an incubation period of 4 h at 37 C, cells that had
migrated to the lower chamber were collected and counted on a
cytofluorimeter (FACSCalibur™, constant time acquisition; Bec-
ton Dickinson). In blocking experiments cells were preincubated
with anti-CCR7 mAb (10  g/ml) and added to the Transwell.
Detection of Apoptosis. Determination of DNA fragmentation
was performed as described previously (65). Inhibitors of kinases
or serine proteases (PD98059 [20  M], LY294002 [10  M],
TPCK [20  M]) were added 60 min before stimulation. Inhibi-
tors had no effect on cell viability or the rate of constitutive apop-
tosis at the indicated concentrations.
Nuclear Extracts and Electrophoretic Mobility Shift Assays. Nu-
clear extracts were prepared according to the method of Schreiber
et al. (66) with some modifications. Stimulation of monocyte-
derived human DCs (107) with control or anti–TREM-2 anti-
body or with LPS was performed for 0.5 or 4 h at 37 C as de-
scribed above. Cells were washed in PBS, resuspended in 10 ml of
ice-cold buffer A (10 mM Tris-HCl, pH 7.9, 60 mM KCl, 1 mM
EDTA, 0.75 mM spermidine, 0.15 mM spermine, 1 mM DTT,
0.5 mM PMSF, 1  g/ml aprotinin, 1  g/ml leupeptin, and 1  g/
ml pepstatin), and incubated for 15 min on ice. Nonidet P-40 was
added from a 10% stock solution to a final concentration of 0.6%,
and samples were vortexed for 10 s. After incubation for 3 min on
ice, samples were centrifuged at 3,000 rpm for 10 min at 4 C.
Nuclei were washed in 10 ml of ice-cold buffer A and resus-
pended in 30 ml of ice-cold buffer C (20 mM Tris-HCl, pH 8,
0.4 M NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 0.5
mM PMSF, 1  g/ml aprotinin, 1  g/ml leupeptin, 1  g/ml pep-
statin, and 25% glycerol). Nuclei were incubated for 30 min at
4 C, and nuclear extracts were separated from debris by centrifu-
gation at 15,000 g for 15 min at 4 C. Protein concentrations were
determined by Bradford assay using Bio-Rad protein assay (Bio-
Rad Laboratories). NF- B consensus and mutant binding sites1114 TREM-2/DAP12 Activates Human Monocyte-derived Dendritic Cells
were 5 -AGTTGAGGGGACTTTCCCAGGC-3  and 5 -AGT-
TGAGGCGACTTTCCCAGGC-3 , respectively. Annealed bind-
ing sites were radiolabeled using polynucleotide T4 kinase and
 [32P]-ATP. Radiolabeled oligonucleotides were purified by elec-
trophoresis through an 8% polyacrylamide gel containing 22.5
mM Tris-borate and 0.5 mM EDTA, overnight elution from gel
slices at 37 C, concentration using Elutip-d columns (Schleicher
& Schuell), and ethanol precipitation. Electrophoretic mobility as-
says (EMSAs) were performed as described previously (67) with
some modifications. Nuclear extracts (2  g) were incubated with
1  g of poly(dI-dC) carrier and 1  g of BSA in a 25  l reaction
mix containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM
DTT, 1 mM EDTA, and 5% glycerol for 10 min at 4 C in the
presence or absence of 25-fold excess of unlabeled oligonucleotide
competitors. Labeled binding-site probes (15 fmols,  5   104
cpm) were then added for an additional 20 min of incubation at
4 C. Samples were electrophoresed through a 4% polyacrylamide
gel containing 22.5 mM Tris-borate and 0.5 mM EDTA at 4 C.
Results
Human Immature Monocyte-derived DCs Express TREM-2,
a  40 kD Glycoprotein which Is Associated with DAP12. In
initial studies, TREM-2 transcript was selectively detected
in monocyte-derived DCs by reverse transcriptase (RT)-
PCR (data not shown). To precisely investigate the cellular
distribution of TREM-2 as well as its biochemical charac-
teristics and functions, we produced an anti–TREM-2
mAb (29E3). This antibody stained TREM-2–transfected
293 cells specifically, compared with control transfectants
(Fig. 1 A). In agreement with RT-PCR data, TREM-2
was highly expressed on DCs derived from peripheral
blood monocytes upon in vitro culture with GM-CSF and
IL-4 (Fig. 1 B). DC maturation induced by LPS, TNF ,
CD40L-expressing cells (Fig. 1 C), IL-1 , CpG oligonu-
cleotides, or aggregated IgG (data not shown) led to com-
plete downregulation of TREM-2. TREM-2 was unde-
tectable on macrophages obtained by culturing monocytes
up to 14 d with M-CSF (Fig. 1 B) and on primary DCs of
peripheral blood (data not shown). Thus, TREM-2 is pref-
erentially expressed on immature monocyte-derived DCs.
Immunoprecipitation of TREM-2 from surface-biotiny-
lated monocyte-derived DCs revealed that TREM-2 is a
glycoprotein of  40 kD, that is reduced to 26 kD after
N-deglycosylation (Fig. 2 A). This result is in agreement
with the predicted molecular mass of TREM-2 (53). As
TREM-2 lacks known signaling motifs in the cytoplasmic
domain and displays a charged residue of lysine in the trans-
membrane domain (53), it was likely to be associated with
a separate adaptor molecule to transduce signals. Adaptor
molecules, such as DAP12, DAP10, and FcR  are tyrosine
phosphorylated upon cell treatment with the phosphatase
inhibitor pervanadate (44, 68, 69). Indeed, anti-phosphoty-
Figure 1. TREM-2 is selectively expressed on immature DCs. (A)
mAb 29E3 recognizes selectively TREM-2. 293 cells transfected with a
cDNA encoding FLAG-tagged TREM-2 (TREM-2FLAG; right panels)
were stained with mAb 29E3 (top panel), compared with cells transfected
with a control cDNA (controlFLAG; left panels). The percentages of posi-
tive cells (top right quadrants) are indicated. Expression of TREM-2FLAG
and controlFLAG was confirmed using an anti-FLAG mAb (bottom pan-
els). Cells stained with an isotype-matched control mAbs were comprised
within the indicated bottom quadrant. (B) TREM-2 is strongly upregu-
lated after stimulation of monocytes with GM-CSF and IL-4. Monocytes
treated with GM-CSF/IL-4 (left panel) or M-CSF (right panel) were an-
alyzed by flow cytometry for cell surface expression of TREM-2 (solid
bold line) after 36 h or up to 14 d, respectively. Dashed profiles indicate
background staining with a control IgG1 mAb. (C) TREM-2 is rapidly
downregulated upon maturation of DCs. LPS- (top right panel), CD40L-
(bottom left panel), TNF -stimulated (bottom right panel), or unstimu-
lated monocyte-derived DCs (top left panel) were analyzed by flow cy-
tometry for cell surface expression of TREM-2 and CD83 after 36 h.
Cells stained with an isotype-matched control mAbs were comprised
within the indicated bottom quadrants.1115 Bouchon et al.
rosine blotting of TREM-2 immunoprecipitates from per-
vanadate-stimulated monocyte-derived DCs revealed a
phosphorylated protein of  14 and  28 kD under reduc-
ing and nonreducing conditions, respectively (Fig. 2 B).
This pattern was consistent with the association of TREM-2
with a tyrosine-phosphorylated protein that forms a disul-
fide-linked homodimer. Immunoblotting of TREM-2 im-
munoprecipitates with anti-DAP12, -DAP10, and -FcR 
antisera demonstrated that TREM-2, like TREM-1, asso-
ciates only with DAP12 (Fig. 2 C, and data not shown).
Thus, TREM-2 is capable of stimulating DAP12-linked
signaling pathways in DCs.
TREM-2 Induces ERK Activation and Survival of DCs.
To see whether the TREM-2/DAP12 complex transduces
activating signals in DCs as other DAP12-associated recep-
tors do in NK cells and neutrophils (43–45, 47–54, 56, 70),
we stimulated TREM-2 with 29E3 mAb or with its F(ab )2
fragment. In both cases, ligation of TREM-2 elicited a
rapid rise in intracellular Ca2  concentration of DCs (Fig. 3
B). However, monovalent engagement of TREM-2 using
F(ab ) 29E3 did not induce calcium mobilization, indicat-
ing that TREM-2–mediated activation needs at least two
or more receptors crosslinked (data not shown). Cross-
linking of TREM-2 with F(ab )2 29E3 stimulated tyrosine
phosphorylation of several proteins with approximate mo-
lecular masses of  110,  90,  60–70, and  30–40 kD
(Fig. 3 C). The observed  40 kD tyrosine phosphorylated
proteins corresponded to the ERK1/2, as demonstrated by
antiphospho-ERK1/2 immunoblotting (Fig. 3 D). It was
previously shown that survival of LPS-stimulated DCs is
dependent on ERK (71) and phosphatidylinositol 3-kinase
(PI-3K) (72), while maturation is mainly mediated through
NF- B. Therefore, we tested whether stimulation of
TREM-2 leads to prolonged survival of DCs kept in cul-
ture in the absence of GM-CSF or IL-4. As shown in Fig.
3 E, crosslinking of TREM-2 with F(ab )2 29E3 prolonged
DC survival for almost 8 d. Treatment of TREM-2–stimu-
lated DCs with the ERK inhibitor PD98059 blocked this
survival effect. Inhibitors of PI-3K, I B-phosphorylation,
or I B-degradation had no effect (Fig. 3 F, and data not
shown). These observations indicate that TREM-2 induces
survival of DCs through activation of the ERK pathway.
TREM-2 Triggers Rapid Upregulation of CCR7 and In-
creased Expression of MHC Class II, CD86, and CD40.
To examine whether TREM-2 can trigger migration of
DCs and/or their maturation into efficient antigen-pre-
senting cells, immature DCs were stimulated with F(ab )2
29E3 mAb coated on plastic surface. These cells were
tested for the expression of cell surface molecules involved
in migration, antigen presentation, costimulation, and ad-
hesion, as well as for the production of cytokines. Upon
TREM-2 ligation, CCR7 surface expression was rapidly
increased (Fig. 4 A). CCR7 was functionally competent,
as TREM-2–stimulated DCs showed a specific chemotac-
tic response towards the CCL19 and CCL21, which could
be inhibited by anti-CCR7 mAb (Fig. 4 B). The ampli-
tude and kinetics of CCR7 upregulation induced via
TREM-2 were different compared with those induced by
Figure 2. TREM-1 is a 40-kD glycoprotein associated with the adap-
tor protein DAP12. (A) Surface-biotinylated monocyte-derived DCs were
lysed and subjected to immunoprecipitation with 29E3 anti–TREM-2
mAb (right lanes) or control IgG1 mAbs (21C7 anti–TREM-1 mAb). Im-
munoprecipitates (IP) were left untreated or treated with N-glycanase F
and analyzed by Western blot analysis with Streptavidine-HRP. Molec-
ular weight markers and specific protein bands are indicated. (B) Pervan-
adate-treated monocyte-derived DCs were subjected to immunoprecip-
itation with 29E3 anti–TREM-2 mAb or control IgG1 mAb (21C7
anti–TREM-1 mAb). The precipitates were analyzed by antiphosphoty-
rosine blot under reducing (left lanes) and nonreducing (right lanes)
conditions. Tyrosine phosphorylated proteins are marked by arrows.
Molecular weight markers are indicated. (C) Anti-DAP12 blot analysis
of TREM-2 immunoprecipitate from monocyte-derived DCs (left
lanes) and monocytes (right lanes) after pervanadate stimulation (reduc-
ing conditions). TREM-1 immunoprecipitates from monocytes and
monocyte-derived DCs were included as positive and negative con-
trols, respectively. Molecular weight markers and specific protein
bands are indicated.1116 TREM-2/DAP12 Activates Human Monocyte-derived Dendritic Cells
LPS stimulation (Fig. 4 A). While expression of CCR7
was detectable by 6 h after TREM-2 stimulation, LPS-
induced upregulation of CCR7 was weaker and occurred
only after 24 h of cell stimulation. Regardless of CCR7
surface levels, however, LPS-stimulated DCs displayed a
stronger chemotactic response toward CCL19 and CCL21
than TREM-2–stimulated DCs. Therefore, DC mobility
and chemotaxis to CCL19 and CCL21 is not solely related
to CCR7 expression levels. Indeed, it has been shown
that other receptors, such as the multidrug resistance-asso-
ciated protein 1, can contribute to optimal mobilization of
DCs from skin to secondary lymphoid organs (73).
Figure 3. Stimulation of monocyte-derived
DCs via TREM-2 induces calcium mobilization,
tyrosine phosphorylation, and prolongs DC sur-
vival by an Erk-dependent pathway. (A) Func-
tional characterization of F(ab ) and F(ab )2 29E3.
Monocyte-derived DCs were analyzed by flow
cytometry for cell surface expression of TREM-2
using either biotinylated F(ab )2 29E3 (solid bold
profile), F(ab ) 29E3 (gray profile), control F(ab )
(dashed profile), or F(ab )2 (solid profile) followed
by Streptavidin-PE. (B) Stimulation of TREM-2
induces intracellular Ca2  mobilization. Bivalent
crosslinking of TREM-2 using IgG1,   29E3, or
Fc-free F(ab )2 29E3 induces intracellular Ca2 
mobilization in contrast to control mAbs (21C7
anti–TREM-1 mAb; left panels; 1A11 anti-
MHC class I mAb; data not shown). (C) An-
tiphosphotyrosine blot of cell lysates from mono-
cyte-derived DCs stimulated with F(ab )2 29E3
(anti–TREM-2) or control F(ab )2 (anti–TREM-1
mAb) for the indicated time periods. (D) Mono-
cyte-derived DCs were stimulated as indicated in
C and examined by Western blot analysis for
anti-phospho-Erk1/2 (top panel) compared with
anti-Erk 1/2 (bottom panel). Arrows indicate
phosphorylated proteins in all panels. Molecular
weight markers are shown. (E) Monocyte-
derived DCs were washed five times to remove
GM-CSF/IL-4 before stimulation with plastic-
bound F(ab )2 29E3 (open circles), control F(ab )2
(21C7 anti–TREM-1 mAb) (filled circles), or
GM-CSF (filled squares) for the indicated time
periods. Apoptotic cell death was determined by
measurement of DNA fragmentation. (F) Mono-
cyte-derived DCs were stimulated plastic-bound
F(ab )2 29E3 in the presence or absence of Erk-
inhibition (PD98059 [20  M]), PI3K-inhibition
(LY294002 [10  M]), or inhibition of I B-deg-
radation (TPCK [20  M]). Apoptotic cell death
was determined after 8 d compared with DCs
stimulated with control F(ab )2 by measuring sub-
diploid DNA content.
Figure 4. Stimulation of TREM-2 induces
CCR7 expression and chemotactic response to-
ward CCL19 and CCL21. (A) CCR7 is rapidly
upregulated after stimulation of TREM-2 on
DCs. DCs were stimulated with F(ab )2 anti–
TREM-2 mAb (gray profiles), control F(ab )2
(21C7; anti–TREM-1; solid line profiles), or
LPS (solid bold profiles). After the indicated
time periods cells were harvested and analyzed
by flow cytometry for cell surface expression of
CCR7 by anti-CCR7 mAb (mouse IgM) fol-
lowed by PE-labeled goat anti–mouse IgM.
Dashed profiles indicate background staining
with a control IgM mAb. (B) TREM-2 stimulation directs migration of DCs toward CCL19 and CCL21 by a CCR7-dependent pathway. DCs stimu-
lated for 24 h with plastic-coated control F(ab )2 (21C7, anti–TREM-1; black bars), F(ab )2 anti–TREM-2 mAb (light gray bars), or LPS (dark gray bars)
were tested in Transwell chemotaxis assays for the ability to migrate toward medium alone, medium supplemented with 100 ng/ml CCL19 or CCL21
(BOTTOM well). In control experiments, DCs were preincubated for 15 min with anti-CCR7 mAb before placing them in the TOP well for assess-
ment of chemotaxis toward medium alone, medium supplemented with CCL19, or CCL21 placed in the BOTTOM well.1117 Bouchon et al.
Ligation of TREM-2 also induced increased cell surface
expression of several molecules involved in T cell stimula-
tion, such as MHC class II, CD40, and CD86 (Table I). In
contrast to LPS-activated DCs, CD83 and intracellular ad-
hesion molecule (ICAM)-1 were not upregulated. Further-
more, antigen-capturing molecules, such as CD32, CD64,
CD89, and the mannose receptor, were not downregulated
(Table I). DCs activated through TREM-2 did not secrete
either IL-12, or other cytokines (Table II). Thus, TREM-2
mediates a unique pattern of DC activation, characterized
by upregulation of CCR7, expression of some T cell stim-
ulatory molecules, and lack of cytokine secretion.
TREM-2 Does Not Activate I B /NF- B or p38/SAPK
Signaling Pathways. LPS-induced maturation of DCs re-
quires the activity of NF- B transcription factor (74–76).
Prior to activation, NF- B is retained in the cytoplasm
through binding to the inhibitory I B protein. Stimulation
of cells with LPS leads to I B kinase (IKK)-mediated phos-
phorylation of I B. This is followed by rapid ubiquitination
and proteolytic degradation of I B, allowing nuclear trans-
location of NF- B and binding to  B-promoter elements
(30–33, 77). To study whether TREM-2 activates the
I B /NF- B pathway, we stimulated DCs through TREM-2
and analyzed the phosphorylation of I B  by Western blot
analysis. In addition, we assessed the nuclear translocation of
NF- B by searching for NF- B–containing complexes in
EMSAs. In striking contrast to LPS (72), antibody-mediated
ligation of TREM-2 did not lead to phosphorylation and
degradation of I B  (Fig. 5 A) or nuclear translocation of
NF- B (Fig. 5 B). It was previously shown that LPS-
induced maturation of DCs is also mediated by activation of
p38/SAPK (72, 78). To see whether TREM-2 activates
p38/SAPK, we crosslinked TREM-2 on DCs with F(ab )2
29E3 and analyzed tyrosine phosphorylation of p38/SAPK
by Western blot analysis. In contrast to LPS, TREM-2 did
not induce p38/SAPK tyrosine phosphorylation (Fig. 5 C).
Table I. TREM-2–dependent Regulation of Cell Surface 
Activation Markers
F(ab )2
anti–TREM-1
F(ab )2
anti–TREM-2 LPS
TREM-2 112.23 3.45 7.1
MHC class I 67.8 65.3 107.1
MHC class II 119.12 278.65 454.67
CD40 171.35 598.6 635.89
CD80 32.1 39.4 104.6
CD86/B7.2 14.04 387.91 683.56
CCR5 12.95 13.56 3.12
CCR6 3.68 3.45 4.01
CCR7 6.82 21.98 12.45
CXCR4 5.13 4.56 17.8
CD11a 10.92 6.78 13.72
CD11b 53.9 65.7 23.1
CD11c 91.1 65.7 123.5
CD29 38.22 37.56 37.5
CD41 4.54 4.67 4.39
CD54/ICAM-1 56.87 54.78 271.45
CD61 4.95 5.03 4.21
CD103 3.63 3.96 3.26
Mannose-R 81.8 82.9 30.9
CD64/Fc R I 9.8 10.1 2.3
CD32/Fc R II 17.21 16.78 2.34
CD89/Fc R 4.54 4.75 4.96
CD35/CR 1 3.94 4.23 3.67
M-CSF-R 14.6 4.23 5.21
GM-CSF-R 15.6 13.7 13.5
CD38 2.5 2.2 43.5
CD83 3.34 3.23 26.7
CD1a 106.76 134.9 87.54
DCs were cultured for 48 h in plates coated with control F(ab )2,
F(ab )2 anti–TREM-2 mAb, or LPS as indicated in Fig. 6. Cells were
subsequently analyzed by flow cytometry for the indicated cell surface
molecules. Numerical values indicate specific mean fluorescence
intensity after subtraction of the fluorescence detected with an isotype-
matched control. The data shown are representative of four
independent experiments.
Table II. Lack of Cytokine and Chemokine Secretion upon 
TREM-2 Engagement
F(ab )2
anti–TREM-1
F(ab )2
anti–TREM-2 LPS
IL-1  N.D. N.D. 0.135   0.026
IL-1  0.027   0.012 N.D. 0.162   0.09
TNF-  0.042   0.005 N.D. 4.015   0.078
IL-18 N.D. N.D. 2.56   1.31
IL-6 N.D. N.D. 16.7   5.43
IL-10 N.D. N.D. 2.03   0.45
TGF- 1 N.D. N.D. N.D.
IL-12p40 N.D. N.D. 3.48   1.25
IL-12p70 N.D. N.D. 1.45   0.09
IL-13 N.D. N.D. N.D.
IL-15 N.D. N.D. N.D.
MCP-1 2.018   0.875 0.449   0.067 98.18   35.86
IL-8 1.23   0.451 0.023   0.01 124.76   23.91
Cells were stimulated as described in Fig. 6. Cell supernatants were
analyzed by ELISA for secretion of the indicated cytokines and
chemokines. Data are representative for three independent experiments.
Values are shown in pg/ml. N.D., not detectable.1118 TREM-2/DAP12 Activates Human Monocyte-derived Dendritic Cells
Thus, the TREM-2–induced activation pathway is NF-
 B- and p38/SAPK independent.
TREM-2 Induces DC Maturation through an ERK- and
PTK-dependent, NF- B, and p38/SAPK-independent Path-
way. To further characterize the signaling molecules in-
volved in TREM-2–mediated DCs maturation, DCs were
incubated with inhibitors of ERK (PD98049), NF- B
(TPCK), p38/SAPK (SB203580), and PTKs (PP2). Treated
cells were stimulated with either F(ab )2 anti–TREM-2
mAb, LPS, or immobilized IgG and subsequently analyzed
for cell surface expression of maturation markers, such as
CCR7, MHC class II, ICAM-1 CD83, CD40, and CD86.
TREM-2 induced upregulation of CCR7, CD86, class II,
and CD40, while cell surface expression of ICAM-1 and
CD83 was not increased (Fig. 6, red bars). Remarkably,
TREM-2–induced expression of CCR7, CD86, class II,
and CD40 was completely blocked by a PTK inhibitor and
partially blocked by an ERK inhibitor. This differential in-
hibitory capacity suggests that PTK may activate down-
stream signaling molecules other than ERK, which concur
to TREM-2–mediated DC maturation. Incubation of DCs
with NF- B and p38/SAPK inhibitors had virtually no ef-
fect (Fig. 6, red bars).
LPS-induced maturation pathway was totally distinct
from that mediated by TREM-2. LPS-induced upregula-
tion of CCR7, MHC class II, ICAM-1 CD83, CD40, and
CD86 (Fig. 6, green bars) (1). Incubation of DCs with NF- B
and p38/SAPK inhibitors prevented LPS-induced matura-
tion, whereas ERK inhibitor had a modest effect, as de-
scribed previously (Fig. 6, green bars) (72, 78). Finally, en-
gagement of FcR by immobilized IgG induced a maturation
pattern, which was similar to that induced by TREM-2,
with the exception of an upregulation of ICAM-1 (Fig. 6,
blue bars). Incubation of DCs with PTK and ERK inhibi-
tors resulted in total and partial inhibition of FcR-induced
maturation, respectively. These observations provide evi-
dence that TREM-2 mediates DC maturation by PTK/
ERK-dependent pathways. These pathways overlap with
those initiated by FcRs, but are distinct from the I B /NF-
 B and p38/SAPK-dependent pathways triggered by LPS.
Discussion
We have shown that TREM-2 is an activating receptor
expressed on monocyte-derived DCs, which activates PTK
and ERK signaling through the association with DAP12,
an ITAM-containing adaptor molecule (44, 45). TREM-
2/DAP12-mediated signaling promotes survival of DCs
Figure 5. TREM-2 does not initiate I B /NF- B- and p38/SAPK-
dependent pathways. (A) Lack of I B  phosphorylation and degradation
upon TREM-2 stimulation of monocyte-derived DCs. Monocyte-
derived DCs were stimulated by LPS or plastic-bound F(ab )2 anti–
TREM-2 mAb or control F(ab )2 for the indicated times. Protein lysates
were tested for I B  phosphorylation and degradation by Western blot
analysis. The same blot was sequentially stripped and reprobed with an-
tiphospho-I B , anti-I B , and anti-actin (loading control) antibod-
ies. (B) Lack of NF- B translocation upon TREM-2 triggering.
Monocyte-derived DCs were stimulated for the indicated time points
as described in panel A and nuclear extracts were obtained. Radiolabeled
NF- B consensus double-stranded oligonucleotides were incubated with
the indicated nuclear extracts in the absence of competing oligonucle-
otides or in the presence of a 25-fold molar excess of wild-type (NF- B)
or mutant (NF- Bmut) competing oligonucleotides. DNA–protein com-
plexes were resolved by electrophoresis. The NF- B–containing complex
is marked. (C) Absence of p38/SAPK phosphorylation upon TREM-2
stimulation of monocyte-derived DCs. Monocyte-derived DCs were
stimulated for the indicated times as described in panel A. Protein lysates
were tested for p38/SAPK phosphorylation (top panel) by Western blot
analysis. The same blot was sequentially stripped and reprobed with anti-
p38/SAPK antibodies (bottom panel). Arrows indicate proteins in all pan-
els. Molecular weight markers are shown. To confirm proper stimulation
of TREM-2/DAP12 in all experimental settings an aliquot of stimulated
DCs was kept and tested after 48 h for upregulation of MHC class II and
CD86 (data not shown).1119 Bouchon et al.
and upregulation of CCR7, MHC class II, CD86, and
CD40. Compared with the classical DC activation trig-
gered by LPS, the TREM2/DAP12 pathway does not lead
to upregulation of ICAM-1 and CD83 or secretion of IL-
12, and is entirely independent of NF- B and p38/SAPK
signaling. TREM2/DAP12-induced DC maturation is
more similar to that initiated by the FcRs, through the as-
sociation FcR , another ITAM-containing adaptor mole-
cule (42). Indeed, here we have shown that FcR-mediated
maturation is dependent on PTK and ERK signaling.
This study is the first to show that a DAP12-mediated
pathway can activate human DCs. What could be the
physiological significance of this maturation pathway?
TREM-2 or other DAP12-associated receptors could syn-
ergize with cell surface receptors, which activate DCs
through NF- B. This possibility is consistent with previous
work on TREM-1, another DAP12-associated myeloid re-
ceptor (53), which is upregulated on neutrophils upon ex-
posure to LPS and synergizes with LPS in promoting in-
flammatory responses to bacterial infections (79, 80). Thus,
DAP12-associated DC receptors could amplify maturation
signals transduced by other receptors, allowing for optimal
antigen presentation. DAP12-mediated DCs activation
could also be important in the normal homeostasis of DCs.
TREM-2 induces upregulation of CCR7, which plays a
pivotal role in directing DCs from the periphery to the T
cell rich areas of draining lymph nodes (10–14). Thus, in
the absence of pathogens, DAP12-associated receptors
could regulate the homeostatic circulation of DCs from the
periphery to the lymph nodes, allowing for renewal of
lymph node DCs. In addition, TREM-2 induces upregula-
tion of some T cell stimulatory molecules, such as MHC
class II, CD40, and CD86. Thus, DAP12-mediated matu-
ration of DCs may promote partial activation of T cells in
the absence of exogenous antigens. This activation presum-
ably is critical for the survival of T cells and the homeostasis
of T cell populations (81).
We have demonstrated that crosslinking of TREM-2
promotes DC survival. This observation is consistent with
previous demonstration that ERK signaling prevents apop-
tosis of LPS-stimulated DCs (71). In addition, we have ev-
idence that TREM-1/DAP12 complex promotes survival
of neutrophils and monocytes (unpublished data). To-
gether, these observations suggest that DAP12-mediated
pathways are critical for myeloid cell survival. Based on our
data and previous studies in other systems, DAP12-medi-
ated ERK activation is likely to induce phosphorylation of
Bad or other Bcl-2 inhibitors (82–84). Once released from
inhibition, Bcl-2 could translocate into the mitochondria
and inhibit DC apoptosis (85–88).
The physiological functions of DAP12-mediated DC ac-
tivation are consistent with the reported phenotypes of
knock-in mice bearing a nonfunctional DAP12 and
DAP12-deficient mice (57, 58). ITAM-deficient DAP12-
knock-in mice showed an accumulation of DCs in muco-
cutaneous epithelia, associated with an impaired hapten-
specific contact sensitivity (57). Our data suggest that this
phenotype may be explained in part by a reduced ability of
DCs to upregulate CCR7 expression and to respond to
CCL19 and CCL21, affecting the migration of DCs to the
T cell zone of draining lymph nodes. DAP12-deficient
mice were resistant to EAE and resistance was associated
with a strongly diminished production of IFN-  by my-
elin-reactive CD4  T cells (58). Our results suggest that this
phenotype may be partly due to a reduced amplification of
chemotactic and maturation signals by DAP12-associated
receptors, resulting in an inadequate T cell priming in vivo.
Human TREM-2 is the first DAP12-associated receptor
identified on DCs. TREM-2 is expressed on immature
monocyte-derived DCs, but not on mature DCs or pri-
mary blood DCs. In addition, mouse TREM-2 transcripts
were recently observed in cultured macrophage cell lines
(54). Thus, more DAP12-associated receptors are likely to
Figure 6. Comparison of TREM-2-, LPS/TLR-, and FcR-mediated
maturation pathways. Monocyte-derived DCs were stimulated with
plastic-bound control F(ab )2 (black bars), F(ab )2 anti–TREM-2 (red
bars), human IgG (blue bars), or LPS (green bars) in the presence of in-
hibitors for Erk (PD98059), p38/SAPK (SB203580), PTK (PP2), I B 
degradation (TPCK), or an equal volume of DMSO as a control. After
48 h, cell surface expression of CD86 (top left panel), MHC class II
(middle left panel), CD40 (bottom left panel), CD83 (top right panel),
ICAM-1 (middle right panel), or CCR7 (bottom right panel) was deter-
mined by flow cytometry. Data shown are representative of four inde-
pendent experiments and display the mean and standard deviation of
three independent samples.1120 TREM-2/DAP12 Activates Human Monocyte-derived Dendritic Cells
be expressed on blood and tissues DCs. In addition, such
receptors might be expressed not only in immature DCs,
but also in mature DCs, regulating critical functions, such
as IL-12 secretion. To fully understand the physiological
functions of DAP12 in DCs, it will be important to identify
all the DAP12-associated DC receptors, their level of ex-
pression in different maturation stages, and their ligands.
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